All In Biotech

Drug Trial Radar · NCT00625898

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab

Last checked: Nov 19, 2026Latest source record: Sep 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 3,509 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

3,509

Actual

Start

Apr 2008

Primary completion

Jun 2013

Study completion Jul 2014

Sponsor

Lead sponsor
NSABP Foundation IncResearch network
Sponsor type
Research network
Collaborators
Cancer International Research Group (CIRG); Hoffmann-La Roche; Genentech, Inc.
First posted
Feb 29, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.

Conditions

  • Breast Cancer

Interventions

  • DocetaxelDrug

    75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B 100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

  • TrastuzumabDrug

    First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

  • CarboplatinDrug

    6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6

  • BevacizumabDrug

    15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B 15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B

  • 5-FluorouracilDrug

    600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

  • EpirubicinDrug

    90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

  • CyclophosphamideDrug

    600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-free Survival (IDFS)Time frame: up to 10 years

Locations

649 sites in 40 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Clearview Cancer Institute-Decatur

    Decatur, Alabama

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Clearview Cancer Institute- Huntsville

    Huntsville, Alabama

  • Northern Arizona Hematology & Onclogy Associates

    Flagstaff, Arizona

  • Northern Arizona Hematology & Oncology Associates

    Sedona, Arizona

  • Central Hematology/Oncology Medical Group, Inc.

    Alhambra, California

  • Comprehensive Blood and Cancer Center

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Providence Saint Joseph Medical Center

    Burbank, California

  • Hematology-Encinitas

    Encinitas, California

  • Scripps Clinic Encinitas

    Encinitas, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • St. Jude Heritage Healthcare

    Fullerton, California

  • Breastlink Medical Group, Inc

    Hawthorne, California

  • Pacific Shores Medical Group

    Huntington Beach, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • Hematology-La Jolla

    La Jolla, California

  • Sabina R. Wallach, MD., AMC

    La Jolla, California

  • Scripps Cancer Center-San Diego

    La Jolla, California

  • Antelope Valley Cancer Center

    Lancaster, California

  • Kaiser Permanente-Sunset

    Los Angeles, California

  • Kaiser Permanente-West Los Angeles

    Los Angeles, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • North County Oncology Medical Clinic, Inc.

    Oceanside, California

  • Kaiser Permanente-Panorama City

    Panorama City, California

  • Kaiser Permanente-Orange County

    Panorama City, California

  • Wilshire Oncology Medical Group

    Pasadena, California

  • Cancer Care Associates Medical Group, Inc.

    Redondo Beach, California

  • Kaiser Permanente-Riverside

    Riverside, California

  • Kaiser Permanente-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Kaiser Permanente-Sacramento

    Roseville, California

  • Sutter Medical Center

    Sacramento, California

  • Sutter Medical Group

    Sacramento, California

  • Peter T. Reissman, MD, Inc

    San Diego, California

  • William Stanton, MD, Inc

    San Diego, California

  • Kaiser Permanente-San Diego

    San Diego, California

  • Sharp Rees-Stealy

    San Diego, California

Showing 40 of 649 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.